Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Unusual Whales
The drug AKTX-101 is progressing through activities preparing for Investigational New Drug (IND) approval to start a Phase 1 clinical trial around mid-2027.
